Quick answerQuestion
prolonged calcitonin monotherapy after the response plateaus.
Why this is correctThe client still needs symptom, calcium, renal, and volume reassessment while longer-acting therapy addresses ongoing malignancy-driven calcium release.
Easy analogy or mental pictureTreat every infusion as a controlled clinical system: verify the product and access, recognize a changing cue, stop preventable exposure, stabilize the client, and confirm the response.
Memory hookProduct, access, compatibility, infusion cue, protective action, and reassessment.NCLEX decision ruleChoose the action that prevents the most immediate infusion-related harm while preserving vascular access and the ordered diagnostic evidence.
Why the other choices are wrongOptions that restart a suspect product, bypass a safety device, force an occluded tube, or delay reassessment can convert a reversible warning into serious harm.
References
1Endocrine Society Clinical Practice Guideline: Hypercalcemia of Malignancy in AdultsInitial hydration, antiresorptive therapy, calcitonin for severe disease, renal and volume assessment, and outcome monitoring